§ Mr. ElletsonTo ask the Secretary of State for Health (1) what representations she has received from the United Kingdom Regional Haemophilia Centre directors' committee about the licensing of pharmaceutical products 681W used in the treatment of people with haemophilia; if she will make it her policy that all people with haemophilia A should be treated with licensed monoclonal high purity products; and if she will make central funds available for this purpose;
(2) if she will make it her policy not to allow unlicensed factor 8 products for the treatment of haemophilia to be imported or used within the United Kingdom.
§ Mr. SackvilleWe have received no such representations from the United Kingdom Regional Haemophilia Centre Directors' Committee. It is normal practice in the United Kingdom for clinicians to use licensed medicinal products. It is also possible for clinicians, under sections 9 and 13 of the Medicines Act, to prescribe an unlicensed product on a "named patient" basis.
It is for clinicians to decide the most appropriate product indicated for the treatment of each individual patient.